NEW YORK (TheStreet) -- CHANGE IN RATINGSBabcock & Wilcox ( BWC was initiated with an Overweight rating at Morgan Stanley. $28 price target. Company has a healthy balance sheet and strong order backlog. Comstock Resources ( CRK was downgraded to Market Perform from Outperform at BMO Capital Markets on limited near-term growth, catalysts and appeal relative to other small-cap names. Price target cut to $30 from $38. Family Dollar ( FDO was upgraded to Overweight from Equal Weight at Barclays. Expect the company to improve its performance steadily in the coming years. Price target raised to $52 from $41. Inergy ( NRGY was upgraded at Wunderlich to Buy from Hold on weakness following the proposed merger with Inergy Holdings ( NRGP. Price target raised to $46 from $40. OGE Energy ( OGE - Get Report) was initiated with a Hold rating at Jefferies. $43 price target. Should benefit from higher commodity prices for Enogex and rate increases at OG&E. TW Telecom ( TWTC was downgraded to Neutral from Buy at Banc of America/Merrill Lynch on multiyear highs in absolute terms and valuation. Price target boosted to $20 from $19.
Frontier Communications ( FTR estimates cut through 2011 at Morgan Stanley. Company is seeing lower sales as it cuts back on promotions. Equal-weight rating. Home Depot ( HD price target cut to $35 from $37 at Barclays. Company will report mixed sales trends for the second quarter, Barclays said. Reiterate Overweight rating. Home Depot ( HD numbers lowered through 2012 at Jefferies. Company will be hurt by lower housing demand. Buy rating and new $33 price target. Lowe's ( LOW price target reduced to $26 from $28 at Barclays. Company will report mixed sales trends for the second quarter. Maintain Overweight rating. Lowe's estimates, target reduced at Jefferies. Shares now seen reaching $24. Estimates also cut, given the weaker sales outlook. Buy rating. McDermott ( MDR estimates, target raised at UBS. Shares now seen reaching $17. Estimates also increased, given the company's solid bookings and higher realized margins. Buy rating. Myriad Genetics ( MYGN estimates reduced through 2012 at Morgan Stanley. Company continues to see decelerating sales growth. Equal-weight rating. Select Medical ( SEM estimates lowered through 2011 at Morgan Stanley. Company is seeing lower volumes and a softer pricing environment. Equal-weight rating. Staples ( SPLS price target lowered to $26 from $28 at Barclays. Expecting cautious second half of the year, Barclays said. Maintain Overweight rating. Sunpower ( SPWRA target upped to $13 at Kaufman Brothers. Company was sold out last quarter. Hold rating. Sunpower price target raised raised to $16.50 from $16.30 at Credit Suisse as the company beat its second-quarter guidance. Maintain Neutral rating. Supervalu ( SVU target lowered to $12.50 at UBS. Company has limited visibility for a sales recovery in the second half of the year. Neutral rating.